Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Qiagen N.V.    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Qiagen: 4Q Earnings Snapshot

share with twitter share with LinkedIn share with facebook
share via e-mail
02/04/2020 | 05:25pm EDT

VENLO, Netherlands (AP) _ Qiagen NV (QGEN) on Tuesday reported fourth-quarter net income of $44.9 million.

On a per-share basis, the Venlo, Netherlands-based company said it had profit of 19 cents. Earnings, adjusted for non-recurring costs, came to 48 cents per share.

The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of 44 cents per share.

The diagnostic products maker posted revenue of $413.5 million in the period, also topping Street forecasts. Five analysts surveyed by Zacks expected $408.9 million.

For the year, the company reported a loss of $41.5 million, or 18 cents per share, swinging to a loss in the period. Revenue was reported as $1.53 billion.

Qiagen expects full-year earnings in the range of $1.52 to $1.54 per share.

Qiagen shares have declined roughly 2% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $33.16, a drop of 10% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on QGEN at https://www.zacks.com/ap/QGEN

Automated Insights, source Associated Press News

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on QIAGEN N.V.
04/07QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
03/31QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
03/31QIAGEN : Receives U.S. FDA EUA for QIAstat-Dx test kit, First and Only Syndromic..
BU
03/26QIAGEN N : ROSEN, A HIGHLY RANKED FIRM, Continues to Investigate Securities Clai..
BU
03/25QIAGEN NV : Warburg Research remains Neutral
MD
03/24QIAGEN N.V. : Notification and public disclosure of transactions by persons
EQ
03/24QIAGEN : Names Thierry Bernard as Chief Executive Officer
BU
03/24QIAGEN : Releases QIAstat-Dx Test Kit to the U.S. as First Syndromic Test for De..
BU
03/20QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
03/18QIAGEN N : launches QIAstat-Dx test kit for detection of SARS-CoV-2 coronavirus ..
PU
More news
Financials (USD)
Sales 2020 1 560 M
EBIT 2020 432 M
Net income 2020 226 M
Debt 2020 925 M
Yield 2020 -
P/E ratio 2020 38,5x
P/E ratio 2021 31,9x
EV / Sales2020 6,46x
EV / Sales2021 5,92x
Capitalization 9 153 M
Chart QIAGEN N.V.
Duration : Period :
Qiagen N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 38,83  $
Last Close Price 40,21  $
Spread / Highest target 6,94%
Spread / Average Target -3,42%
Spread / Lowest Target -22,9%
EPS Revisions
Managers
NameTitle
Thierry Bernard Chief Executive Officer
Sven Håkan Björklund Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Roland Sackers Chief Financial Officer & Managing Director
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN N.V.18.96%9 153
LONZA GROUP13.73%31 009
CELLTRION, INC.2.35%25 160
IQVIA HOLDINGS INC.-22.54%20 797
SEATTLE GENETICS, INC.6.66%19 875
INCYTE CORPORATION-2.53%15 874